Androgen deprivation by activating the liver X receptor

Endocrinology

Volumn 149, Issue 8, 2008, Pages 3778-3788

  Jung, Hoon Lee ^a   Gong, Haibiao ^a   Khadem, Shaheen ^a   Lu, Yi ^b   Gao, Xiang ^a   Li, Song ^a   Zhang, Jian ^b   Xie, Wen ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; HYDROXYSTEROID SULFOTRANSFERASE; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; STEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CASTRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; EXPERIMENTAL MOUSE; HOMEOSTASIS; HORMONE ACTION; HORMONE INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SULFONATION; TISSUE REGENERATION;

ANDROGENS; ANIMALS; BENZOIC ACIDS; BENZYLAMINES; CELLS, CULTURED; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDROXYCHOLESTEROLS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, HORMONE-DEPENDENT; ORPHAN NUCLEAR RECEPTORS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REGENERATION; SULFOTRANSFERASES; TESTOSTERONE;

EID: 47949088159     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-1605     Document Type: Article

References (63)

1. Chatterjee B 2003 The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem 253:89-101
2. Denmeade SR, Isaacs JT 2002 A history of prostate cancer treatment. Nat Rev Cancer 2:389-396
3. Long RM, Morrissey C, Fitzpatrick JM, Watson RW 2005 Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci (Lond) 108:1-11
4. American Cancer Society 2006 Cancer facts and figures. New York: American Cancer Society
5. Trapman J, Brinkmann AO 1996 The androgen receptor in prostate cancer. Pathol Res Pract 192:752-760
6. Heinlein CA, Chang C 2004 Androgen receptor in prostate cancer. Endocr Rev 25:276-308
7. Strott CA 2002 Sulfonation and molecular action. Endocr Rev 23:703-732
8. Nagata K, Yamazoe Y 2000 Pharmacogenetics of sulfotransferase. Annu Rev Pharmacol Toxicol 40:159-176
9. Strott CA 1996 Steroid sulfotransferases. Endocr Rev 17:670-697
10. Glatt H, Boeing H, Engelke CE, Ma L, Kuhlow A, Pabel U, Pomplun D, Teubner W, Meinl W 2001 Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat Res 482:27-40
11. Raftogianis RB, Zalatoris JJ, Walther SF 1998 The role of pharmacogenetics in cancer therapy, prevention, and risk. Fox Chase Cancer Center Scientific Report 243-247
12. Meloche CA, Sharma V, Swedmark S, Andersson P, Falany CN 2002 Sulfation of budesonide by human cytosolic sulfotransferase, dehydroepiandrosterone-sulfotransferase (DHEA-ST). Drug Metab Dispos 30:582-585
13. Song CS, Jung MH, Kim SC, Hassan T, Roy AK, Chatterjee B 1998 Tissue-specific and androgen-repressible regulation of the rat dehydroepiandrosterone sulfotransferase gene promoter. J Biol Chem 273:21856-21866
14. Chan J, Song CS, Matusik RJ, Chatterjee B, Roy AK 1998 Inhibition of androgen action by dehydroepiandrosterone sulfotransferase transfected in PC-3 prostate cancer cells. Chem Biol Interact 109:267-278
15. Chatterjee B, Song CS, Jung MH, Chen S, Walter CA, Herbert DC, Weaker FJ, Mancini MA, Roy AK 1996 Targeted overexpression of androgen receptor with a liver-specific promoter in transgenic mice. Proc Natl Acad Sci USA 93:728-733
16. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP 2006 Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815-2825
17. Geese WJ, Raftogianis RB 2001 Biochemical characterization and tissue distribution of human SULT2B1. Biochem Biophys Res Commun 288:280-289
18. Reed MJ, Perohit A, Woo LWL, Newman SP, Potter BVL 2005 Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev 26: 171-202
19. Repa JJ, Mangelsdorf DJ 2002 The liver X receptor gene team: potential new players in atherosclerosis. Nat Med 8:1243-1248
20. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B 2000 Role of LXRs in control of lipogenesis. Genes Dev 14:2831-2838
21. Collins JL, Fivush AM, Watson MA, Galardi CM, Lewis MC, Moore LB, Parks DJ, Wilson JG, Tippin TK, Binz JG, Plunket KD, Morgan DG, Beaudet EJ, Whitney KD, Kliewer SA, Willson TM 2002 Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J Med Chem 45:1963-1966
22. Zelcer N, Tontonoz P 2006 Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 116:607-614
23. Barish GD, Evans RM 2004 PPARs and LXRs: atherosclerosis goes nuclear. Trends Endocrinol Metab 15:158-165
24. Glass CK, Ogawa S 2006 Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 6:44-55
25. Uppal H, Saini SP, Moschetta A, Mu Y, Zhou J, Gong H, Zhai Y, Ren S, Michalopoulos GK, Mangelsdorf DJ, Xie W 2007 Activation of LXRs prevents bile acid toxicity and cholestasis in female mice. Hepatology 45:422-432
26. Mukai M, Dong Q, Hardy MP, Kiyokawa H, Peterson RE, Cooke PS 2005 Altered prostatic epithelial proliferation and apoptosis, prostatic development, and serum testosterone in mice lacking cyclin-dependent kinase inhibitors. Biol Reprod 73:951-958
27. Uppal H, Toma D, Saini SP, Ren S, Jones TJ, Xie W 2005 Combined loss of orphan receptors PXR and CAR heightens sensitivity to toxic bile acids in mice. Hepatology 41:168-176
28. Saini SP, Sonoda J, Xu L, Toma D, Uppal H, Mu Y, Ren S, Moore DD, Evans RM, Xie W 2004 A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol Pharmacol 65:292-300
29. Gong H, Guo P, Zhai Y, Zhou J, Uppal H, Jarzynka MJ, Song WC, Cheng SY, Xie W 2007 Estrogen deprivation and inhibition of breast cancer growth in vivo through activation of the orphan nuclear receptor liver X receptor. Mol Endocrinol 21:1781-1790
30. Louie MC, Yang HQ, Ma AH, Xu W, Zou JX, Kung HJ, Chen HW 2003 Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex. Proc Natl Acad Sci USA 100:2226-2230
31. English HF, Santen RJ, Isaacs JT 1987 Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 11:229-242
32. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA 2004 Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431:707-712
33. Ellwood-Yen K, Wongvipat J, Sawyers C 2006 Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. Cancer Res 66:10513-10516
34. Jiang YJ, Kim P, Elias PM, Feingold KR 2005 LXR and PPAR activators stimulate cholesterol sulfotransferase type 2 isoform 1b in human keratinocytes. J Lipid Res 46:2657-2666
35. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ 2000 Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ. Genes Dev 14:2819-2830
36. Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, Tontonoz P 2001 Autoregulation of the human liver X receptor α promoter. Mol Cell Biol 21:7558-7568
37. Rehse PH, Zhou M, Lin SX 2002 Crystal structure of human dehydroepiandrosterone sulphotransferase in complex with substrate. Biochem J 364(Pt 1):165-171
38. Lee KA, Fuda H, Lee YC, Negishi M, Strott CA, Pedersen LC 2003 Crystal structure of human cholesterol sulfotransferase (SULT2B1b) in the presence of pregnenolone and 3′-phosphoadenosine 5′-phosphate. Rationale for specificity differences between prototypical SULT2A1 and the SULT2B1 isoforms. J Biol Chem 278:44593-44599
39. Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventos CX, Catalan R, Reventos J 2006 Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int 77:135-138
40. Kinouchi T, Maeda O, Ono Y, Meguro N, Kuroda M, Usami M 2002 Failure to maintain the suppressed level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer. Int J Urol 9:359-361
41. Saner KJ, Suzuki T, Sasano H, Pizzey J, Ho C, Strauss 3rd JF, Carr BR, Rainey WE 2005 Steroid sulfotransferase 2A1 gene transcription is regulated by steroidogenic factor 1 and GATA-6 in the human adrenal. Mol Endocrinol 19:184-197
42. Cummins CL, Volle DH, Zhang Y, McDonald JG, Sion B, Lefrancois-Martinez AM, Caira F, Veyssiere G, Mangelsdorf DJ, Lobaccaro JM 2006 Liver X receptors regulate adrenal cholesterol balance. J Clin Invest 116:1902-1912
43. Turgeon D, Carrier JS, Levesque E, Hum DW, Belanger A 2001 Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778-787
44. Buckley DB, Klaassen CD 2007 Tissue- and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice. Drug Metab Dispos 35:121-127
45. Takase Y, Luu-The V, Poisson-Pare D, Labrie F, Pelletier G 2007 Expression of sulfotransferase 1E1 in human prostate as studied by in situ hybridization and immunocytochemistry. Prostate 67:405-409
46. Tontonoz P, Mangelsdorf DJ 2003 Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17:985-993
47. Joseph SB, Bradley MN, Castrillo A, Bruhn KW, Mak PA, Pei L, Hogenesch J, O'Connell R M, Cheng G, Saez E, Miller JF, Tontonoz P 2004 LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119:299-309
48. Valledor AF, Hsu LC, Ogawa S, Sawka-Verhelle D, Karin M, Glass CK 2004 Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc Natl Acad Sci USA 101:17813-17818
49. Choe SS, Choi AH, Lee JW, Kim KH, Chung JJ, Park J, Lee KM, Park KG, Lee IK, Kim JB 2007 Chronic activation of liver X receptor induces β-cell apoptosis through hyperactivation of lipogenesis: liver X receptor-mediated lipotoxicity in pancreatic β-cells. Diabetes 56:1534-1543
50. Wente W, Brenner MB, Zitzer H, Gromada J, Efanov AM 2007 Activation of liver X receptors and retinoid X receptors induces growth arrest and apoptosis in insulin-secreting cells. Endocrinology 148:1843-1849
51. Fukuchi J, Kokontis JM, Hiipakka RA, Chuu CP, Liao S 2004 Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res 64:7686-7689
52. Chuu CP, Hiipakka RA, Kokontis JM, Fukuchi J, Chen RY, Liao S 2006 Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res 66:6482-6486
53. Lindzey J, Wetsel WC, Couse JF, Stoker T, Cooper R, Korach KS 1998 Effects of castration and chronic steroid treatments on hypothalamic gonadotropin-releasing hormone content and pituitary gonadotropins in male wild-type and estrogen receptor-α knockout mice. Endocrinology 139:4092-4101
54. Volle DH, Mouzat K, Duggavathi R, Siddeek B, Dechelotte P, Sion B, Veyssiere G, Benahmed M, Lobaccaro JM 2007 Multiple roles of the nuclear receptors for oxysterols liver X receptor to maintain male fertility. Mol Endocrinol 21:1014-1027
55. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y, Moriya T, Ito A, Takahashi S, Yamada S, Arai Y, Sasano H 2005 In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 12:101-107
56. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M 2004 The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64:765-771
57. Freeman MR, Solomon KR 2004 Cholesterol and prostate cancer. J Cell Biochem 91:54-69
58. Swinnen JV, Brusselmans K, Verhoeven G 2006 Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 9:358-365
59. Hager MH, Solomon KR, Freeman MR 2006 The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care 9:379-385
60. Song C, Liao S 2001 Hypolipidemic effects of selective liver X receptor α agonists. Steroids 66:673-681
61. Kaneko E, Matsuda M, Yamada Y, Tachibana Y, Shimomura I, Makishima M 2003 Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist. J Biol Chem 278:36091-36098
62. Repa JJ, Mangelsdorf DJ 1999 Nuclear receptor regulation of cholesterol and bile acid metabolism. Curr Opin Biotechnol 10:557-563
63. Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, Sparrow CP, Lund EG 2001 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem 276:38378-38387